<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="118">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 13, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02214420</url>
  </required_header>
  <id_info>
    <org_study_id>PJPIIS-01-14</org_study_id>
    <nct_id>NCT02214420</nct_id>
  </id_info>
  <brief_title>SMV + SOF With/Without RBV for IFN-II Patients With CHC</brief_title>
  <official_title>Simeprevir (SMV) + Sofosbuvir (SOF) With or Without Ribavirin (RBV) for Interferon-intolerant or Ineligible (IFN-II) Patients With Chronic Hepatitis C (CHC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SC Liver Research Consortium, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SC Liver Research Consortium, LLC</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prior trials have shown that many G1 CHC patients are ineligible or intolerant to PEG-based
      regimens due to prior severe side effects, worsening of cytopenias, exacerbation of
      underlying psychiatric disorders, or autoimmune disorders. These patients will not be
      candidates for treatment with the approvals of SMV and SOF in early 2014 due to the
      combination with PEG-regimens. Results of the COSMOS study suggest that these patients are
      likely to have excellent responses to SMV+SOF with or without RBV with 12 weeks of therapy,
      and that 24 weeks are unnecessary. This trial is designed to rapidly enroll and be completed
      in order to confirm this hypothesis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sustained Viral Response</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Comparison of SVR12 in 2 arms of IFN-II patients: one receiving 12 weeks of SMV (150mg QD)+SOF (400mg QD) and the second receiving to SMV (150mg QD)+SOF (400mg QD)+weight-based RBV 1000-1200 mg/day.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>SMV+SOF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SMV+SOF+RBV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IFN-II patients will receive 12 weeks of OLYSIO (Simeprevir) (150mg QD) + SOVALDI (Sofosbuvir) (400mg QD) + weight-based Ribavirin 1000-1200 mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simeprevir</intervention_name>
    <arm_group_label>SMV+SOF</arm_group_label>
    <arm_group_label>SMV+SOF+RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <arm_group_label>SMV+SOF</arm_group_label>
    <arm_group_label>SMV+SOF+RBV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <arm_group_label>SMV+SOF+RBV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Targeted at least 20% enrollment of patients with cirrhosis

          2. Adults &gt;/= age 18 years.

          3. Active infection with HCV genotype 1

          4. Must have health insurance that covers therapy with SOF+RBV

          5. Female patients of childbearing age must have a negative pregnancy test prior to
             initiating therapy, use at least two effective methods of contraception during
             treatment, and undergo monthly pregnancy tests.

          6. Patients must be either IFN-ineligible due to psychiatric, autoimmune, neurological,
             or other causes that are confirmed appropriate by the PI; OR,

          7. IFN-intolerant due to flu-like symptoms, psychiatric problems, cytopenia or other
             causes deemed appropriate by the PI.

        Exclusion Criteria:

          1. Presence of HIV co-infection

          2. Presence of HCC

          3. Prior organ transplantation

          4. Any history of hepatic decompensation

          5. Patients taking any of the following medications:

               -  Anticonvulsants- Carbamazepine, Oxcarbazepine, Phenobarbital, or Phenytoin.

               -  Anti-infectives-erythromycin, clarithromycin, or telithromycin.

               -  Antifungals- systemic itraconazole, ketoconazole, posaconazole, fluconazole, or
                  voriconazole.

               -  Antimycobacterials- rifampin, rifabutin or rifapentine.

               -  Corticosteroids- systemic dexamethasone.

               -  Propulsives- Cisapride.

               -  Herbals- Milk thistle or St. John's Wart.

          6. Patients that have been exposed to direct acting anti-viral agents

          7. Patients with severe renal impairment (estimated Glomerular Filtration Rate (eGFR)
             &lt;50 mL/min/1.73m2) or with end stage renal disease (ESRD).

          8. Patients with platelet count &lt;50 x109/L, Hemoglobin &lt;10 g/dL, or Neutrophils &lt;0.5
             x109/L.

          9. Women who are pregnant.

         10. Men whose partners are pregnant or plan on becoming pregnant.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Pockros, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ronda Willis, MBA</last_name>
    <phone>858-692-9887</phone>
    <email>willis.ronda@scliver.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shari Gilbert, RN</last_name>
      <phone>858-652-5421</phone>
      <email>gilbert.shari@scrippshealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Kaye Waite, RN</last_name>
      <phone>858-652-5438</phone>
      <email>Waite.Kaye@scrippshealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Paul Pockros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mt. Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Baez, MA</last_name>
      <phone>212-241-8903</phone>
      <email>elizabeth.baez@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Ritu Agarwal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centers of America, LLC</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 27, 2015</lastchanged_date>
  <firstreceived_date>August 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>SC Liver Research Consortium, LLC</investigator_affiliation>
    <investigator_full_name>Paul J. Pockros, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Simeprevir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
